On March 28, 2025, Chengdu Weijin Baiao Biomedical Technology Co., Ltd., a member of Chengdu High-tech Medical Association, announced that its Phase I clinical trial application for VG712, an innovative anti-T cell immunotoxin protein, for the treatment of peripheral T-cell lymphoma (PTCL) has been implicitly approved by the U.S. Food and Drug Administration (FDA). This is another important milestone for VG712 in the field of T-cell malignancies, following the indication of cutaneous T-cell lymphoma (CTCL).

Peripheral T-cell lymphomas (PTCLs) are a group of highly aggressive non-Hodgkin lymphomas that account for approximately 10% to 15% of all lymphomas. Patients often have rapid lymphadenopathy enlargement, systemic symptoms, and multi-organ invasion, and the 5-year survival rate of existing treatment regimens is less than 30%, and there is a lack of effective treatment after recurrence. VG712 is expected to bring the opportunity of prolonging life and even cure for PTCL patients by specifically targeting the dual mechanism of T cells, which is to eliminate the malignant T cell population and rebuild the patient's own anti-tumor function.

The development of PTCL indication has further demonstrated that VG712 can bring a wide range of clinical value by restarting T cell immune function.

**About Chengdu Weijin Baiao Biomedical Technology Co., Ltd.**

Viche Biotech is a clinical-stage biotechnology company with a team that has accumulated deep expertise and rich experience in international product development. The company's core project, VG712, was invented by Dr. David Neville, an immunotoxin pioneer, at the National Institutes of Health (NIH). Different from traditional immunotoxin or ADC drugs, VG712 can quickly eliminate T cells in the body and have a short-lived effect, while cleverly avoiding the trigger of cytokine storm, which can restart the body's cellular immune function. Through this unique mechanism, it has cured a number of patients with advanced tumors in early clinical studies and obtained the qualification of rapid review by the US FDA. Vijin Biotech has the exclusive global development and sales rights of VG712, has completed the production of drugs for global clinical trials, and is fully deploying a number of clinical studies in major fields including tumor and organ rejection.